| Title |
Melatonergic drugs in development
|
|---|---|
| Published in |
Clinical Pharmacology : Advances and Applications, September 2014
|
| DOI | 10.2147/cpaa.s36600 |
| Pubmed ID | |
| Authors |
Alessia Carocci, Alessia Catalano, Maria Stefania Sinicropi |
| Abstract |
Melatonin (N-acetyl-5-methoxytryptamine) is widely known as "the darkness hormone". It is a major chronobiological regulator involved in circadian phasing and sleep-wake cycle in humans. Numerous other functions, including cyto/neuroprotection, immune modulation, and energy metabolism have been ascribed to melatonin. A variety of studies have revealed a role for melatonin and its receptors in different pathophysiological conditions. However, the suitability of melatonin as a drug is limited because of its short half-life, poor oral bioavailability, and ubiquitous action. Due to the therapeutic potential of melatonin in a wide variety of clinical conditions, the development of new agents able to interact selectively with melatonin receptors has become an area of great interest during the last decade. Therefore, the field of melatonergic receptor agonists comprises a great number of structurally different chemical entities, which range from indolic to nonindolic compounds. Melatonergic agonists are suitable for sleep disturbances, neuropsychiatric disorders related to circadian dysphasing, and metabolic diseases associated with insulin resistance. The results of preclinical studies on animal models show that melatonin receptor agonists can be considered promising agents for the treatment of central nervous system-related pathologies. An overview of recent advances in the field of investigational melatonergic drugs will be presented in this review. |
Mendeley readers
The data shown below were compiled from readership statistics for 75 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 3% |
| United States | 1 | 1% |
| Unknown | 72 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 16 | 21% |
| Student > Bachelor | 14 | 19% |
| Researcher | 9 | 12% |
| Student > Doctoral Student | 5 | 7% |
| Student > Ph. D. Student | 5 | 7% |
| Other | 10 | 13% |
| Unknown | 16 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 16% |
| Agricultural and Biological Sciences | 11 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 11% |
| Neuroscience | 7 | 9% |
| Nursing and Health Professions | 5 | 7% |
| Other | 17 | 23% |
| Unknown | 15 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 October 2023.
All research outputs
#3,885,854
of 25,806,080 outputs
Outputs from Clinical Pharmacology : Advances and Applications
#35
of 180 outputs
Outputs of similar age
#38,508
of 249,558 outputs
Outputs of similar age from Clinical Pharmacology : Advances and Applications
#2
of 5 outputs
Altmetric has tracked 25,806,080 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 180 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 249,558 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.